New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
- PMID: 35469489
- DOI: 10.1177/10781552221096165
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients. In recent years there have been several new therapeutic agents approved for the treatment of relapsed/refractory DLBCL, thereby expanding the therapeutic landscape. These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. This review summarizes the pharmacology, efficacy, safety, dosing, and administration of new agents recently approved for the treatment of relapsed/refractory DLBCL.
Keywords: CAR T-cell; antibody drug conjugate; lymphoma; pharmacotherapy.
Similar articles
-
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.Transplant Cell Ther. 2023 Jul;29(7):440-448. doi: 10.1016/j.jtct.2023.04.003. Epub 2023 Apr 7. Transplant Cell Ther. 2023. PMID: 37031747 Review.
-
Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390802. doi: 10.1200/EDBK_390802. Am Soc Clin Oncol Educ Book. 2023. PMID: 37098236
-
Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.JAMA Netw Open. 2022 Dec 1;5(12):e2245956. doi: 10.1001/jamanetworkopen.2022.45956. JAMA Netw Open. 2022. PMID: 36520440 Free PMC article.
-
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.Eur J Haematol. 2023 Dec;111(6):895-908. doi: 10.1111/ejh.14095. Epub 2023 Aug 29. Eur J Haematol. 2023. PMID: 37644352
-
Novel agents in relapsed/refractory diffuse large B-cell lymphoma.Hematol Oncol. 2023 Jun;41 Suppl 1:92-106. doi: 10.1002/hon.3143. Hematol Oncol. 2023. PMID: 37294966 Review.
Cited by
-
Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis.Adv Radiat Oncol. 2024 Apr 27;9(7):101524. doi: 10.1016/j.adro.2024.101524. eCollection 2024 Jul. Adv Radiat Oncol. 2024. PMID: 38799107 Free PMC article.
-
Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.Clin Exp Med. 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. Clin Exp Med. 2024. PMID: 38554186 Free PMC article.
-
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.Hemasphere. 2022 Nov 11;6(12):e798. doi: 10.1097/HS9.0000000000000798. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
